Literature DB >> 19057260

The CXCR4/SDF-1 chemokine receptor axis: a new target therapeutic for non-small cell lung cancer.

Shannon Otsuka1, Gwyn Bebb.   

Abstract

Chemokines are proinflammatory chemoattractant cytokines that regulate cell trafficking and adhesion. The CXCR4 chemokine receptor and its ligand, stromal cell derived factor (SDF-1), constitute a chemokine/receptor axis that has attracted great interest because of an increasing understanding of its role in cancer, including lung cancer. The CXCR4/SDF-1 complex activates several pathways that mediate chemotaxis, migration and secretion of angiopoietic factors. Neutralization of SDF-1 by anti-SDF-1 or anti-CXCR4 monoclonal antibody in preclinical in vivo studies results in a significant decrease of non-small cell lung cancer metastases. Since anti-SDF-1/CXCR4 strategies have already been developed for use in combating human immunodeficiency virus infections, it is likely that these approaches will be used in clinical trials in non-small cell lung cancer in the very near future.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19057260     DOI： 10.1097/JTO.0b013e31818dda9d

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


  24 in total

1.  The expression of CXCL12 and CXCR4 in gastric cancer and their correlation to lymph node metastasis.

Authors:  Jieer Ying; Qi Xu; Gu Zhang; Bixia Liu; Liming Zhu
Journal:  Med Oncol       Date:  2011-06-01       Impact factor: 3.064

2.  Potentiation of EBV-induced B Cell transformation by CXCR4-tropic, but not CCR5-tropic, HIV gp120: implications for HIV-associated lymphomagenesis.

Authors:  Sujatha Iyengar; David H Schwartz
Journal:  AIDS Res Hum Retroviruses       Date:  2010-11-23       Impact factor: 2.205

Review 3.  Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Authors:  Paul A Bunn; John D Minna; Alexander Augustyn; Adi F Gazdar; Youcef Ouadah; Mark A Krasnow; Anton Berns; Elisabeth Brambilla; Natasha Rekhtman; Pierre P Massion; Matthew Niederst; Martin Peifer; Jun Yokota; Ramaswamy Govindan; John T Poirier; Lauren A Byers; Murry W Wynes; David G McFadden; David MacPherson; Christine L Hann; Anna F Farago; Caroline Dive; Beverly A Teicher; Craig D Peacock; Jane E Johnson; Melanie H Cobb; Hans-Guido Wendel; David Spigel; Julien Sage; Ping Yang; M Catherine Pietanza; Lee M Krug; John Heymach; Peter Ujhazy; Caicun Zhou; Koichi Goto; Afshin Dowlati; Camilla Laulund Christensen; Keunchil Park; Lawrence H Einhorn; Martin J Edelman; Giuseppe Giaccone; David E Gerber; Ravi Salgia; Taofeek Owonikoko; Shakun Malik; Niki Karachaliou; David R Gandara; Ben J Slotman; Fiona Blackhall; Glenwood Goss; Roman Thomas; Charles M Rudin; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2016-01-30       Impact factor: 15.609

4.  Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors.

Authors:  Miodrag Dragoj; Jasna Bankovic; Evangelia Sereti; Sofija Jovanovic Stojanov; Konstantinos Dimas; Milica Pesic; Tijana Stankovic
Journal:  Invest New Drugs       Date:  2017-07-22       Impact factor: 3.850

5.  Stemness-Related Markers in Cancer.

Authors:  Wenxiu Zhao; Yvonne Li; Xun Zhang
Journal:  Cancer Transl Med       Date:  2017-06-08

6.  Overlapping and distinct role of CXCR7-SDF-1/ITAC and CXCR4-SDF-1 axes in regulating metastatic behavior of human rhabdomyosarcomas.

Authors:  Katarzyna Grymula; Maciej Tarnowski; Marcin Wysoczynski; Justyna Drukala; Frederic G Barr; Janina Ratajczak; Magdalena Kucia; Mariusz Z Ratajczak
Journal:  Int J Cancer       Date:  2010-12-01       Impact factor: 7.396

7.  Differential expression of SDF-1 isoforms in bladder cancer.

Authors:  Miguel Gosalbez; Marie C Hupe; Soum D Lokeshwar; Travis J Yates; John Shields; Muthu K Veerapen; Axel S Merseburger; Charles J Rosser; Mark S Soloway; Vinata B Lokeshwar
Journal:  J Urol       Date:  2013-11-26       Impact factor: 7.450

8.  The balance between two isoforms of LEF-1 regulates colon carcinoma growth.

Authors:  Shu-Hong Wang; Ke-Jun Nan; Yao-Chun Wang; Wen-Juan Wang; Tao Tian
Journal:  BMC Gastroenterol       Date:  2012-05-28       Impact factor: 3.067

9.  Peripheral immune cell gene expression changes in advanced non-small cell lung cancer patients treated with first line combination chemotherapy.

Authors:  Yung-Che Chen; Chang-Chun Hsiao; Kuang-Den Chen; Yu-Chiang Hung; Ching-Yuan Wu; Chien-Hao Lie; Shih-Feng Liu; Ming-Tse Sung; Chung-Jen Chen; Ting-Ya Wang; Jen-Chieh Chang; Petrus Tang; Wen-Feng Fang; Yi-Hsi Wang; Yu-Hsiu Chung; Tung-Ying Chao; Sum-Yee Leung; Mao-Chang Su; Chin-Chou Wang; Meng-Chih Lin
Journal:  PLoS One       Date:  2013-02-25       Impact factor: 3.240

Review 10.  CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential.

Authors:  Ori Wald; Oz M Shapira; Uzi Izhar
Journal:  Theranostics       Date:  2013-01-13       Impact factor: 11.556
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.